According to a Wikipedia definition, a presentation is the act of giving something to someone in a formal way. This should not just be a narration of information or data; ideally, a presentation should contain a story, which means that a plot, characters and a narrative point of view need to be included. All of the established types of presentation, i.e., oral abstract presentations, abstract discussions and education symposia, can be created to match this requirement.

In 2013, Japanese researchers launched a nationwide, prospective, observational study for patients with lung cancer and genomic alterations, called Lung Cancer Genomic Screening Project for Individualized Medicine in Japan (LC-SCRUM-Japan). The number of participating institutions has risen greatly over time, and today 241 institutions from almost all regions across the country are part of the project.

Most of the targeted agents currently recommended for the treatment of lung cancer are administered as single agents. However, there is a rationale for combinations, as two drugs might act in an additive or synergistic manner and may control different populations of tumor cells. Tumor heterogeneity plays a major role here, especially in patients who have already developed resistance to their first treatment.

In the setting of a clinical study, sample data are used to make an inference for the entire population. Generally speaking, results from a randomized clinical trial (RCT) will be unlikely to be exactly the same as population parameters, which is the reason for bias involved. In addition, when a RCT were repeated 100 times, results obtained each time would not be identical, which is the reason for uncertainty involved.

A career as a physician scientist can be extremely fulfilling, as it is an opportunity to make a difference in patient care by way of academic excellence. Clinical observations are explored in the translational setting based on experience and prior knowledge; eventually, the insights gained in this way can give rise to clinical innovation.

From 8th to 10th December, 2017, 15 young oncologists from Japan, Singapore, Taiwan, Korea and Vietnam convened in Singapore to participate in the Japanese Society of Medical Oncology (JSMO) Young Oncologist Preceptorship that was held under the guidance of a panel of renowned experts in the field of lung cancer.